|
2025
|
Invention
|
Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms i... |
|
|
Invention
|
Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells. The invent... |
|
|
Invention
|
Humanized bcma antibody and bcma-car-t cells.
The present invention is directed to a humanized B... |
|
|
Invention
|
Modified cascade ribonucleoproteins and uses thereof.
A clustered regularly interspaced short pa... |
|
2024
|
Invention
|
Treatment of autoimmune diseases with engineered immune cells.
The invention comprises methods a... |
|
|
Invention
|
Methods and compositions for improving precision of endonuclease-mediated genome editing. Disclos... |
|
|
Invention
|
In vitro validation methods for car-t cell therapies. The invention includes improved methods and... |
|
|
Invention
|
In vitro validation methods for cd19-targeting cell therapies. The invention includes improved me... |
|
|
Invention
|
Diagnostic and therapeutic methods for use with ror1 antagonists. The invention is a method of de... |
|
|
Invention
|
Treatment of autoimmune diseases with bcma-targeting engineered immune cells. The invention compr... |
|
|
Invention
|
Anti-ror1 antibody and ror1-targeting engineered cells.
The present invention is directed to a m... |
|
2023
|
G/S
|
Anti-cancer preparations; biological preparations made from human blood cells for the treatment o... |
|
|
Invention
|
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods. An anti-CD371 (anti-... |
|
|
Invention
|
Anti-ror1 chimeric antigen receptors (cars), cells expressing the cars and related methods.
The ... |
|
|
Invention
|
Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods. The invention comp... |
|
|
G/S
|
Pharmaceutical and biological preparations for the treatment of cancer; pharmaceutical and biolog... |
|
|
Invention
|
Treatment of autoimmune diseases with engineered immune cells. The invention comprises methods an... |
|
|
Invention
|
Cytokine-receptor fusions for immune cell stimulation. A fusion protein of IL-21 cytokine and IL-... |
|
|
Invention
|
Anti-ror1 antibody and ror1-targeting engineered cells. The present invention is directed to a mo... |
|
|
Invention
|
Compositions and methods of nucleic acid-targeting nucleic acids.
This disclosure provides for c... |
|
|
Invention
|
Therapeutic applications of crispr type v systems. The present disclosure provides methods and co... |
|
2022
|
Invention
|
Method of capturing crispr endonuclease cleavage products. The invention is a method of capturing... |
|
|
Invention
|
A method of capturing crispr endonuclease cleavage products. The invention is a method of capturi... |
|
|
Invention
|
Exonuclease-coupled real-time endonuclease activity assay.
The invention comprises a rapid in vi... |
|
|
Invention
|
Exonuclease-coupled real-time endonuclease activity assay. in vitro in vitro method of assessing ... |
|
|
Invention
|
Crispr hybrid dna/rna polynucleotides and methods of use.
The present disclosure provides DNA-gu... |
|
|
Invention
|
Methods and materials for treating cancer using car constructs with an intracellular domain compr... |
|
|
Invention
|
Humanized bcma antibody and bcma-car-t cells. L having the amino acid sequence of SEQ ID NO: 5. T... |
|
|
G/S
|
pharmaceutical and biological preparations for the treatment of cancer; pharmaceutical and biolog... |
|
2021
|
Invention
|
Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and us... |
|
|
Invention
|
Bcma-car-natural killer (nk) cells and methods related thereto. L having the amino acid sequence ... |
|
|
Invention
|
Methods of use of crispr cpf1 hybrid dna/rna polynucleotides. The present disclosure provides DNA... |
|
|
Invention
|
Modified cascade ribonucleoproteins and uses thereof. A clustered regularly interspaced short pal... |
|
2020
|
Invention
|
Engineered cascade components and cascade complexes. The present disclosure provides engineered C... |
|
|
Invention
|
Crispr abasic restricted nucleotides and crispr accuracy via analogs.
The present disclosure pro... |
|
|
Invention
|
Crispr abasic restricted nucleotides and crispr accuracy via analogs. The present disclosure prov... |
|
|
Invention
|
Method of target cleaving using crispr hybrid dna/rna polynucleotides. The present disclosure pro... |
|
|
Invention
|
Engineered nucleic-acid targeting nucleic acids. The present disclosure provides engineered cross... |
|
|
Invention
|
Plasmids for gene editing. The present invention pertains to single plasmid systems comprising se... |
|
2019
|
Invention
|
Suicide module compositions and methods. Chimeric transmembrane proteins comprising one or more s... |
|
|
G/S
|
scientific analysis services in the field of genome editing. |
|
2018
|
Invention
|
Modified lymphocytes.
Modified lymphocytes that ectopically express an endogenous gene of intere... |
|
|
G/S
|
Genome engineering reagents. Scientific research services in the fields of biotechnology, cellula... |
|
2017
|
G/S
|
[ genome engineering reagents for scientific and research use ] [ scientific research services in... |
|
|
G/S
|
Genome engineering reagents. Scientific research in the fields of biotechnology, cellular enginee... |
|
|
G/S
|
Scientific analysis services in the field of genome editing |
|
2015
|
G/S
|
[ genome engineering reagents ] Scientific research in the fields of biotechnology, cellular engi... |
|
2014
|
G/S
|
Biotechnologically-formed genes for use in the modification of plants and animals for research pu... |
|
|
G/S
|
[ genome editing and amplification reagents ] Genome editing and amplification; scientific study ... |
